Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician (Q28265412)

Europe PubMed Central

title

Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician (English)

0 references

0 references

0 references

1 reference

Bianca Weinstock-Guttman

8

object named as

Bianca Weinstock-Guttman

0 references

Howard L. Weiner

7

object named as

Howard Weiner

0 references

author name string

Aaron Boster

1

0 references

Gilles Edan

2

0 references

Elliott Frohman

3

0 references

Adil Javed

4

0 references

Olaf Stuve

5

0 references

Alexandros Tselis

6

0 references

Omar Khan

Current treatment options in multiple sclerosis

9

0 references

language of work or name

English

0 references

publication date

February 2008

0 references

published in

Lancet Neurology

0 references

volume

7

0 references

issue

2

0 references

page(s)

173-83

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

High-dose cyclophosphamide without stem-cell rescue for refractory CIDP

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Interleukin-12: Amiss in MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Immunosuppressive treatment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Multiple sclerosis: long-term remission after a high dose of cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Pharmacokinetics and metabolism of mitoxantrone. A review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

An open-trial evaluation of mitoxantrone in the treatment of progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Rationale for the use of mitoxantrone in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Bone marrow transplantation in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Autologous stem cell transplantation in progressive multiple sclerosis--an interim analysis of efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Engineering of therapeutic antibodies to minimize immunogenicity and optimize function

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

α4Integrins as Therapeutic Targets in Autoimmune Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

A controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

CAMPATH-1H in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Rituximab: expanding role in therapy for lymphomas and autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

The use of antibodies against the IL-2 receptor in transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Cyclophosphamide for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Cyclophosphamide-induced hemorrhagic cystitis in Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Severe cystitis induced by cyclophosphamide. Role of surgical management

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Fertility preservation: a comprehensive approach to the young woman with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

The safety profile of cyclophosphamide in multiple sclerosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Acute nonlymphocytic leukemia following short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Acute Myelogenous Leukemia Following ImmunosuppressiveTherapy for Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Identifying and treating patients with suboptimal responses

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Mitoxantrone for multiple sclerosis causing acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Mitoxantrone in progressive multiple sclerosis: when and how to treat?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Management of worsening multiple sclerosis with mitoxantrone: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Prognostic factors in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

A study of tremor in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021

MRI of spinal cord in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970020-6

7 January 2021